Microbiome Therapeutics Europe is organized by KNect365 Life Sciences and will be held from Mar 28 - 29, 2019 at Courtyard by Marriott Vienna Prater/Messe, Vienna, Wien, Austria.
This conference leaders from across the field of microbiome therapeutics will gathering in Vienna to discuss the latest research, developments and discoveries in the pursuit to translate the power of the human microbiome into commercially viable medicines.
Over 2 days, Microbiome Therapeutics Europe will explore the ins and outs of emerging technologies, learnings from clinical trials, regulatory hurdles and commercial challenges to help you gain the information and connections you need to take your pipeline to the next level.
Join the likes of AOBiome, AMC Amsterdam, Merck, Eligo Bioscience, The BioCollective, BioMarketing Insight, Evolve Biosystems Inc. and more for practical industry insights, and discuss manufacturing and formulation strategies to take these projects from concepts to market.
Plus, stay up-to-date of the regulatory framework developments and seek out investment opportunities to ensure you're equipped with the information you need for your products to succeed.
For sponsorship and exhibition opportunities please contact Perri.Lucatello@KNect365.com
Time: 08:00 to 16:20
Speakers: Larry Weiss, CEO and Founder at Persona Biome, Raul Cano, CSO at The BioCollective, Todd Krueger, Chief Executive Officer and President at AOBiome, Xavier Duportet, CEO at Eligo Bioscience, Regine Au, Principal at BioMarketing Insight, Michel De Baar, Executive Director, Business Development, Europe at Merck, Wouter De Jonge, Professor of NeuroGastroenterology at AMC Amsterdam, Marielle Fournier, Senior Director, Drugs, Devices and Combination Products at Voisin Consulting Life Sciences, Philippe Galant, CSO at SYNGULON, François Gianelli, Associate Director at Voisin Consulting Life Sciences, Scott Jackson, Leader - Complex Microbial Systems Group, Biosystems and Biomaterials Division at National Institute of Standards and Technology, Nikole Kimes, Founder/Vice President at Siolta Therapeutics, David Kyle, Chairman and CSO at Evolve Biosystems Inc., Daniel McDonald, Scientific Director at American Gut Project, Julian Riba, CSO at Cytena, Ricardo Valladares, Vice President, Research and Development at Siolta Therapeutics, Momo Vuyisich, Chief Science Officer at Viome, Inc
Additional details will be posted as soon as they are available.
|Registration Type||Due Date||Price|
|Academic Conference Fee||27 Mar,2019||GBP 999.00|
|standard Conference Fee||27 Mar,2019||GBP 1499.00|
|Registration Type||End Date||Price|
|Academic Early Fee||15 Feb,2019||GBP 799.00|
|Standard Early Fee||15 Feb,2019||GBP 1299.00|